Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals Inc (NQ: ANEB )

2.422 -0.065 (-2.61%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.